CMR Substances in EU Cosmetics: How CLP Reclassifications Create Overnight Formulation Bans

There’s a particular type of regulatory risk that keeps cosmetic safety assessors awake at night — and it has nothing to do with a new law being passed or a new Annex being published. It’s the quiet, technical update buried inside a Corrigendum to the CLP Regulation that reclassifies an ingredient your product already contains. One morning, a substance you’ve been using for years is a Category 2 CMR. By the next ATP (Adaptation to Technical Progress) cycle, it’s a Category 1B. And under Article 15 of Regulation (EC) No 1223/2009, that reclassification doesn’t require a cosmetics-specific amendment — the prohibition is automatic.

That mechanism is widely misunderstood, even by experienced formulators. Let’s work through how it actually functions, what the compliance obligations look like in practice, and where brands most consistently fall short.

What Article 15 of Regulation 1223/2009 Actually Says — And What It Doesn’t

Article 15 establishes the core rule: substances classified as CMR 1A or 1B under CLP (Regulation (EC) No 1272/2008) are prohibited in cosmetic products. The prohibition applies as soon as a substance carries that classification in Annex VI of CLP — there is no additional cosmetics-specific legislative step required to activate the ban.

This is not how most product categories work. In food, for example, a substance being classified as hazardous doesn’t automatically remove it from an approved list; separate regulatory action is required. In cosmetics, the bridge between CLP classification and market prohibition is structurally direct.

There is a derogation pathway, but it’s narrow. Under Article 15(2), a CMR 1A or 1B substance can remain permitted in cosmetics if, after evaluation by the Scientific Committee on Consumer Safety (SCCS), three conditions are simultaneously satisfied: the substance is safe for use in cosmetics, no suitable alternative substances exist, and the substance is used in a specific product type only. This path has been used — titanium dioxide in certain spray formats has been the subject of exactly this kind of scrutiny — but it’s the exception, not a workaround brands should plan around.

CMR Category 2 substances are handled differently. They’re not automatically prohibited. Instead, they’re evaluated on a case-by-case basis and may remain permitted pending SCCS review. But “may remain permitted” is not the same as “automatically permitted,” and the evidentiary burden during an inspection falls on the brand.

The CLP ATP Cycle: Why Your Safety Assessor Should Read Every Single One

The Harmonised Classification and Labelling list in Annex VI of Regulation 1272/2008 is updated through Adaptations to Technical Progress — ATPs. These are delegated regulations published in the Official Journal of the EU, typically numbered as “Regulation (EU) [number]/[year] amending Regulation (EC) No 1272/2008.” As of mid-2026, the 21st ATP is in effect, with further amendments in the pipeline.

Each ATP can run to hundreds of pages. The critical entries — the ones that affect cosmetics formulations — are rarely flagged in any summary document specifically for the cosmetics industry. ECHA publishes harmonised classification proposals during the dossier consultation phase, and Cosmetics Europe issues regulatory bulletins for members, but there’s no systematic alert mechanism that automatically connects a CLP change to a cosmetics formulation review. That connection has to be made manually, by a qualified safety assessor who reads the right sources.

In practice, several ingredient categories have seen CMR reclassification pressure in recent ATPs:

• Certain fragrance components, including some musks and nitromusks, have been under ongoing classification review for reproductive toxicity (Repr. 2, moving toward Repr. 1B in some cases).
• Titanium dioxide (TiO2) was classified as a suspected human carcinogen (Carc. 1B by inhalation) in the 14th ATP. This triggered the now-well-known compliance question for spray products — but many smaller brands only learned about it after inspections.
• Certain formaldehyde-releasing preservatives, while not always classified as CMR directly, sit in a regulatory zone where their breakdown products face ongoing scrutiny.
• Resorcinol and related compounds have faced evolving reproductive toxicant classification discussions at ECHA level.

The list changes. Treating your formulation’s compliance as a one-time clearance event — “we got the safety report signed off in 2021, we’re fine” — is simply not how Article 15 compliance works.

The Mechanics of an Annex II Addition via CMR Reclassification

When a substance is newly classified as CMR 1A or 1B in an ATP, the prohibition under Article 15(1) is technically immediate upon the CLP amendment entering into force. However, the practical enforcement timeline is more nuanced.

The European Commission subsequently incorporates the prohibition into Annex II of Regulation 1223/2009 through a formal amendment. This cosmetics-specific amendment can lag the CLP reclassification by 12 to 24 months — sometimes longer. During that window, the substance is technically prohibited by Article 15 but not yet listed in Annex II.

This creates a false sense of security for brands that only monitor Annex II additions. If your compliance system is set up to trigger a formulation review only when Annex II is updated, you’re systematically late. The prohibition is in force from the date of the CLP amendment, not from the date of the Annex II addition.

The SCCS’s notes of guidance for the testing of cosmetic ingredients (currently in its 11th revision) and ECHA’s REACH and CLP helpdesk outputs are more timely indicators of incoming restrictions than waiting for Annex II to be formally updated.

What Your Product Information File Needs to Reflect

Under Article 11 of Regulation 1223/2009, the Product Information File (PIF) must be kept up to date and available for inspection by competent authorities. The cosmetic product safety report — Part B of the PIF — must include a safety assessment that reflects the current regulatory status of every ingredient.

When a CLP reclassification occurs, the PIF should be reviewed and, where necessary, updated. The safety assessor who signs off on Part B carries personal professional responsibility for that sign-off. A PIF that lists a CMR 1A or 1B substance as compliant — even if the Annex II addition is still pending — is a documentation liability.

In practice, competent authorities in France (via DGCCRF and ANSM), Germany (via BfR/BVL), and the Nordic countries have demonstrated willingness to enforce Article 15 directly, without waiting for formal Annex II incorporation. A market withdrawal order issued by a national authority doesn’t require Annex II to have been updated first.

For brands with products already on the market, the obligation is to monitor, assess, and act. Reformulation timelines for a CMR-affected ingredient can run from 6 months to 2 years depending on the function of the substance and the complexity of the formulation — which means the monitoring system needs to identify risks well upstream of the ATP entering into force.

The Specific Challenge for Multi-Market Brands

European brands selling simultaneously into the EU, the UK, the US, and Canada face a compounded challenge: CMR classification under CLP doesn’t automatically translate to equivalent restrictions in other jurisdictions.

The UK, post-Brexit, maintains the UK CLP (which has diverged from EU CLP), and the UK Cosmetics Regulation (retained EU law, as amended) operates on a similar Article 15 mechanism but updates independently. An ingredient reclassified in EU CLP may or may not face simultaneous reclassification in UK CLP — and the UK Office for Product Safety and Standards enforces against the UK classification.

In the United States, the FDA’s approach under MoCRA does not use the CLP framework at all. A CMR 1B classification in the EU doesn’t automatically trigger any action in the US market. However, if the same substance is on California’s Proposition 65 list (as a carcinogen, reproductive toxicant, or developmental toxicant), California-specific warning requirements apply — entirely independently of EU CLP.

For Canadian NHP and cosmetics products, Health Canada’s Cosmetic Ingredient Hotlist operates on its own assessment schedule. Our colleagues at Androxa handle Health Canada compliance for European brands entering Canada, and the classification logic differs materially from the EU Article 15 mechanism.

The practical implication: a multi-market brand cannot manage ingredient compliance from a single regulatory dataset. The monitoring systems need to be jurisdiction-specific, and the remediation decisions — reformulate, withdraw, or seek derogation — need to account for which markets are affected and on what timeline.

Building a Practical CMR Monitoring System

There’s no single official alert service that does all of this automatically. Here’s what a functional monitoring system looks like in practice:

Track ECHA’s Harmonised Classification dossier pipeline. ECHA publishes CLH (Harmonised Classification and Labelling) dossiers at the proposal stage, with public consultation periods. This is typically 12 to 24 months before an ATP enters into force — enough lead time to assess reformulation risk and begin supplier conversations.

Subscribe to Cosmetics Europe regulatory bulletins. Even if you’re not a direct member, the secondary reporting from Cosmetics Europe through consultancy networks provides early warning of incoming classification concerns. The European Federation for Cosmetic Ingredients (EFfCI) similarly tracks ingredient-specific classification developments.

Cross-reference your formulation against Annex VI of CLP annually, at minimum. The complete Annex VI table with current classifications is available in machine-readable format from ECHA’s website. Running a comparison of your active ingredient list against the current Annex VI — flagged for Category 2, 1A, and 1B CMR entries — is a 2–4 hour exercise that should happen at least once per year, and ideally every time an ATP enters into force.

Brief your safety assessor on any CLP change that touches your formulations, not just the ones that produce an immediate prohibition. A Category 2 classification today may move to Category 1B in the next ATP. Getting ahead of that transition while the substance is still a Category 2 CMR — when no prohibition is in force — allows for an orderly reformulation rather than a crisis response.

Engage your contract laboratory early for alternative ingredient validation. When reformulation becomes necessary, the safety assessor will need supporting data for any new ingredient: stability data, challenge testing for preservative efficacy, skin sensitisation assessment (typically via DPRA/h-CLAT or existing LLNA data), and eye irritation data where relevant. Assembling that package takes time — time that a late-detected CLP reclassification won’t give you.

The most dangerous compliance gap isn’t the ingredient you knowingly added — it’s the one that became illegal while your product was already sitting on retail shelves. The Article 15 mechanism means that gap can open silently, without any cosmetics-specific announcement, triggered entirely by a technical update to a regulation that most cosmetics formulators don’t read.

That’s not a comfortable position for any brand, and it’s exactly why CMR monitoring needs to be a standing, scheduled process — not a reactive one.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Need help auditing your EU formulations against current CLP classifications and Article 15 obligations? Contact us

Related from our network

• ISO 17025-accredited ingredient testing for EU cosmetic safety reports — Qalitex Laboratories provides analytical testing data that supports CPSR documentation for EU-marketed products.
• Health Canada Cosmetic Hotlist and NHP compliance for European brands entering Canada — Androxa handles Canadian regulatory submissions and ingredient compliance assessments for international brands.